Literature DB >> 22825586

Prevention and treatment of type 1 diabetes mellitus by the manipulation of invariant natural killer T cells.

Jan Novak1, Lucie Novakova.   

Abstract

Invariant natural killer T (iNKT) cells are CD1d-restricted T cells with regulatory functions. iNKT cells are numerically and functionally deficient in experimental models of type 1 diabetes mellitus (T1DM). Moreover, various experimental strategies correcting the defect of or stimulating iNKT cells prevent T1DM. Here, we review the data on the role of iNKT cells in the development of T1DM and discuss indications, obstacles and prospects of the use of iNKT cell manipulations in the prevention and treatment of human T1DM.

Entities:  

Mesh：

Year:  2012        PMID： 22825586     DOI： 10.1007/s10238-012-0199-0

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN： 1591-8890            Impact factor:   3.984


  89 in total

Review 1.  NKT cells: what's in a name?

Authors:  Dale I Godfrey; H Robson MacDonald; Mitchell Kronenberg; Mark J Smyth; Luc Van Kaer
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

2.  NOD mice contain an elevated frequency of iNKT17 cells that exacerbate diabetes.

Authors:  Yannick Simoni; Anne-Sophie Gautron; Lucie Beaudoin; Linh-Chi Bui; Marie-Laure Michel; Xavier Coumoul; Gérard Eberl; Maria Leite-de-Moraes; Agnès Lehuen
Journal:  Eur J Immunol       Date:  2011-11-10       Impact factor: 5.532

Review 3.  Raising the NKT cell family.

Authors:  Dale I Godfrey; Sanda Stankovic; Alan G Baxter
Journal:  Nat Immunol       Date:  2010-02-07       Impact factor: 25.606

4.  NKT-cell-based immunotherapies in clinical trials.

Authors:  Mark A Exley; Toshinori Nakayama
Journal:  Clin Immunol       Date:  2011-04-28       Impact factor: 3.969

5.  Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes.

Authors:  S B Wilson; S C Kent; K T Patton; T Orban; R A Jackson; M Exley; S Porcelli; D A Schatz; M A Atkinson; S P Balk; J L Strominger; D A Hafler
Journal:  Nature       Date:  1998-01-08       Impact factor: 49.962

6.  Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice.

Authors:  Miho Mizuno; Makoto Masumura; Chiharu Tomi; Asako Chiba; Shinji Oki; Takashi Yamamura; Sachiko Miyake
Journal:  J Autoimmun       Date:  2004-12       Impact factor: 7.094

7.  Prevention of diabetes in nonobese diabetic mice mediated by CD1d-restricted nonclassical NKT cells.

Authors:  Nadia Duarte; Martin Stenström; Susana Campino; Marie-Louise Bergman; Marie Lundholm; Dan Holmberg; Susanna L Cardell
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

8.  TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes.

Authors:  Mériam Belghith; Jeffrey A Bluestone; Samia Barriot; Jérôme Mégret; Jean-François Bach; Lucienne Chatenoud
Journal:  Nat Med       Date:  2003-08-24       Impact factor: 53.440

9.  Cutting edge: V alpha 14-J alpha 281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice.

Authors:  Lennart T Mars; Véronique Laloux; Karine Goude; Sabine Desbois; Abdelhadi Saoudi; Luc Van Kaer; Hans Lassmann; André Herbelin; Agnès Lehuen; Roland S Liblau
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

10.  Up-regulation of CD1d expression restores the immunoregulatory function of NKT cells and prevents autoimmune diabetes in nonobese diabetic mice.

Authors:  Marika Falcone; Federica Facciotti; Nadia Ghidoli; Paolo Monti; Stefano Olivieri; Luca Zaccagnino; Ezio Bonifacio; Giulia Casorati; Francesca Sanvito; Nora Sarvetnick
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422
View more
  2 in total

1.  NK and NKT-like cells in granulomatous and fibrotic lung diseases.

Authors:  L Bergantini; P Cameli; M d'Alessandro; C Vagaggini; R M Refini; C Landi; M G Pieroni; M Spalletti; P Sestini; E Bargagli
Journal:  Clin Exp Med       Date:  2019-09-04       Impact factor: 3.984

Review 2.  Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents.

Authors:  Leandro J Carreño; Noemí A Saavedra-Ávila; Steven A Porcelli
Journal:  Clin Transl Immunology       Date:  2016-04-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.